| NCT06418711 | ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension | RECRUITING | PHASE3 | 2024-09-11 | 2028-12-01 | 2026-08-01 |
| NCT06532942 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers | RECRUITING | PHASE1 | 2024-05-28 | 2024-10-31 | 2024-10-31 |
| NCT05904743 | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes | COMPLETED | PHASE4 | 2023-07-07 | 2024-06-24 | 2024-03-26 |
| NCT05243628 | Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes | COMPLETED | PHASE4 | 2022-03-31 | 2022-10-17 | 2022-10-17 |
| NCT04974528 | Afrezza® INHALE-1 Study in Pediatrics | COMPLETED | PHASE3 | 2021-09-29 | 2025-04-29 | 2024-10-03 |
| NCT04849845 | Afrezza® Dosing Optimization Study | COMPLETED | PHASE4 | 2021-04-09 | 2021-05-28 | 2021-05-28 |
| NCT03464864 | Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers | COMPLETED | PHASE1 | 2018-03-09 | 2018-06-05 | 2018-06-05 |
| NCT02527265 | Afrezza Safety and Pharmacokinetics Study in Pediatric Patients | COMPLETED | PHASE2 | 2017-09-28 | 2020-06-25 | 2020-03-17 |
| NCT02485327 | PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) | COMPLETED | PHASE1 | 2015-07 | 2015-11 | 2015-11 |
| NCT02470637 | Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus | COMPLETED | PHASE1 | 2015-06 | 2015-09 | 2015-09 |
| NCT01982604 | Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers | COMPLETED | PHASE1 | 2013-11 | 2014-08 | 2014-02 |
| NCT01902121 | Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge | COMPLETED | PHASE1 | 2013-08 | 2014-08 | 2013-11 |
| NCT01544881 | Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes | COMPLETED | PHASE1 | 2012-03 | 2013-01 | 2012-09 |
| NCT01490762 | Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler | COMPLETED | PHASE1 | 2011-12 | 2012-07 | 2012-05 |
| NCT01451398 | Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2011-11 | 2013-07 | 2013-06 |
| NCT01445951 | Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period | COMPLETED | PHASE3 | 2011-09 | 2013-06 | 2013-05 |
| NCT01365117 | Pharmacokinetic Study in Healthy Volunteers | COMPLETED | PHASE1 | 2011-01 | 2011-04 | 2011-02 |
| NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | TERMINATED | PHASE2 | 2010-10 | 2012-07 | 2011-09 |
| NCT01196104 | Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler | TERMINATED | PHASE3 | 2010-09 | 2012-03 | 2011-08 |
| NCT00642616 | Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease | TERMINATED | PHASE3 | 2009-03 | 2014-11 | 2014-11 |
| NCT00747006 | Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake | TERMINATED | PHASE2 | 2008-09 | 2011-05 | 2011-02 |
| NCT00757367 | A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL) | COMPLETED | PHASE1 | 2008-07 | 2008-10 | 2008-10 |
| NCT00688090 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. | COMPLETED | PHASE1 | 2008-06 | 2010-05 | 2009-12 |
| NCT00700622 | Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks | TERMINATED | PHASE3 | 2008-05 | 2010-03 | 2009-11 |
| NCT00673621 | A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics | COMPLETED | PHASE1 | 2008-05 | 2008-12 | 2008-11 |
| NCT00674050 | A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers | COMPLETED | PHASE1 | 2008-05 | 2008-10 | 2008-09 |
| NCT00662857 | A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro | COMPLETED | PHASE2 | 2008-04 | 2008-12 | 2008-11 |
| NCT00721344 | A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration. | COMPLETED | PHASE1 | 2008-04 | 2008-10 | 2008-08 |
| NCT00642538 | A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus | COMPLETED | PHASE1 | 2008-02 | 2008-09 | 2008-09 |
| NCT00570687 | A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes | COMPLETED | PHASE2 | 2007-09 | 2009-01 | 2009-01 |
| NCT00626249 | Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function | COMPLETED | PHASE1 | 2007-08 | 2008-10 | 2008-09 |
| NCT00475371 | A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males | COMPLETED | PHASE1 | 2007-04 | | 2007-06 |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | COMPLETED | PHASE1 | 2007-02 | 2009-11 | 2009-09 |
| NCT01021891 | A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE1 | 2006-07 | 2008-11 | 2008-08 |
| NCT00332826 | Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma | TERMINATED | PHASE3 | 2006-06 | 2007-10 | 2007-10 |
| NCT00309244 | Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up | COMPLETED | PHASE3 | 2006-02 | 2008-09 | 2008-08 |
| NCT00308308 | Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes | COMPLETED | PHASE3 | 2006-02 | 2008-08 | 2008-07 |
| NCT00539890 | Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2005-11 | 2006-07 | |
| NCT00308737 | Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes | COMPLETED | PHASE3 | 2005-06 | 2008-10 | 2008-09 |
| NCT00539396 | A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine | COMPLETED | PHASE2 | 2005-03 | 2005-12 | |
| NCT00332488 | Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes | COMPLETED | PHASE3 | 2004-12 | | 2008-03 |
| NCT00934414 | Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes | COMPLETED | PHASE2 | 2004-08 | 2006-09 | 2006-08 |
| NCT00511732 | 18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2004-06 | 2007-08 | 2005-08 |
| NCT00754624 | An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial | COMPLETED | PHASE2 | 2004-05 | 2008-10 | 2008-06 |
| NCT00511719 | Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes | COMPLETED | PHASE2 | 2004-02 | 2005-03 | 2004-04 |
| NCT00511602 | Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2003-12 | 2005-12 | 2004-11 |
| NCT00419302 | To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus. | COMPLETED | PHASE2 | 2003-10 | 2004-04 | |
| NCT00033228 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | COMPLETED | PHASE1, PHASE2 | 2002-01 | 2003-04 | 2003-03 |
| NCT00023647 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | COMPLETED | PHASE1 | 2000-07 | 2002-11 | 2002-04 |
| NCT00511979 | Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin | COMPLETED | PHASE1 | 1999-08 | 2000-06 | 2000-02 |